Effect of P2Y12 platelet reactivity level on peri-and postoperative outcomes of cardiac surgery patients

被引:0
|
作者
Chilbert, Maya R. [1 ,2 ,4 ]
Salah, Sara [1 ]
Kersten, Brian [1 ,2 ]
Nitsche, Lindsay [3 ]
Castoro, Nicole [1 ]
El-Ashry, Awad [2 ]
机构
[1] Univ Buffalo, Sch Pharm & Pharmaceut Sci, Buffalo, NY 14216 USA
[2] Buffalo Gen Med Ctr, Buffalo, NY USA
[3] Jacobs Sch Med & Biomed Sci, Buffalo, NY USA
[4] Univ Buffalo, Sch Pharm & Pharmaceut Sci, Dept Pharm Practice, Div Outcomes & Practice Advancement OPA, 202 Pharm Bldg, Buffalo, NY 14216 USA
来源
JOURNAL OF CARDIOVASCULAR SURGERY | 2023年 / 64卷 / 04期
关键词
Coronary artery bypass; Blood platelets; Hemorrhage; BYPASS SURGERY; CLOPIDOGREL; COMPLICATIONS; INHIBITION; THERAPY; UPDATE; ASSAY; RISK;
D O I
10.23736/S0021-9509.23.12595-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Evidence surrounding P2Y12 platelet reactivity units (PRU) impact on bleeding outcomes in patients undergoing coronary artery bypass is varied. This study sought to assess whether on-pump CABG procedures result in increased bleeding in patients with high comMETHODS: This retrospective cohort study compared those with a PRU level 5237 (low PRU group) to >237 (high PRU group). The primary outcome assessed massive or severe bleeding in accordance with universal definition of perioperative bleeding criteria. Secondary outcomes assessed mortality, length of stay and relevant bleeding related outcomes (e.g., rates of moderate or lower classifications of bleeding, chest tube RESULTS: A total of 69 patients were included, 47 in the low and 22 in the high PRU groups. Patients were a median (IQR) 66 (62-74) years and 84.1% (N.=58) were male. Most patients received clopidogrel prior to procedure (39 [83%] in low and 18 [81.8%] in high PRU group; P=1.0000). The rate of the primary outcome was 14.9% (N.=7) in patients with a low PRU and 18.2% (N.=4) in patients with a high PRU; P=0.7345. The rate of moderate bleeding was 59.6% (N.=28) in the low and 27.3% (N.=6) in the high PRU group (P=0.0124). Packed red blood cells (PRBCs) were administered to more patients in the low (23 [48.9%]) than the high PRU group (2 [22.7%]; P=0.0388). There were no differences in other blood product requirement, chest tube output, factor products administered, mortality, or length of stay. CONCLUSIONS: This study determined that low preoperative P2Y12 PRU levels may influence moderate bleeding in patients undergoing cardiac surgery, but not massive or severe bleeding. (Cite this article as: Chilbert MR, Salah S, Kersten B, Nitsche L, Castoro N, El-Ashry A. Effect of P2Y12 platelet reactivity level on peri- and post
引用
收藏
页码:443 / 449
页数:7
相关论文
共 50 条
  • [31] THE EFFECT OF CESSATION OF 2ND GENERATION P2Y12 INHIBITOR THERAPY ON PLATELET REACTIVITY IN PATIENTS AFTER ACUTE MYOCARDIAL INFARCTION
    Witberg, Guy
    Bathish, Jalal
    Solodky, Alejandro
    Bental, Tamir
    Kornowski, Ran
    Lev, Eli
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 73 - 73
  • [32] Platelet Reactivity And Circulating Platelet-Derived Microvesicles Are Differently Affected By P2Y12 Receptor Antagonists
    Chyrchel, Bernadeta
    Drozdz, Anna
    Dlugosz, Dorota
    Stepien, Ewa L.
    Surdacki, Andrzej
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2019, 16 (02): : 264 - 275
  • [33] Cell Surface Platelet Tissue Factor Expression: Regulation by P2Y12 and Link to Residual Platelet Reactivity
    Brambilla, Marta
    Becchetti, Alessia
    Rovati, Gian Enrico
    Cosentino, Nicola
    Conti, Maria
    Canzano, Paola
    Giesen, Peter L. A.
    Loffreda, Alessia
    Bonomi, Alice
    Cattaneo, Marco
    De Candia, Erica
    Podda, Gian Marco
    Trabattoni, Daniela
    Werba, Pablo Jose
    Campodonico, Jeness
    Pinna, Christian
    Marenzi, Giancarlo
    Tremoli, Elena
    Camera, Marina
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2023, 43 (10) : 2042 - 2057
  • [34] P2Y12 INHIBITION IN ACS: PLATELET AND BEYOND PLATELET EFFECTS
    Badimon, L.
    Mendieta, G.
    Casani, L.
    Vilahur, G.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2017, 121 : 23 - 23
  • [35] Effects of P2Y12 inhibition on platelet function in renal transplant patients
    Graff, J
    Klinkhardt, U
    Gossmann, J
    Wahl, O
    Harder, S
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2004, 369 : R153 - R153
  • [36] Residual platelet ADP reactivity after clopidogrel treatment is dependent on activation of both the unblocked P2Y1 and the P2Y12 receptor and is correlated with protein expression of P2Y12
    Braun, Oscar Oe
    Amisten, Stefan
    Wihlborg, Anna-Karin
    Hunting, Karen
    Nilsson, David
    Erlinge, David
    PURINERGIC SIGNALLING, 2007, 3 (03) : 195 - 201
  • [37] Residual platelet ADP reactivity after clopidogrel treatment is dependent on activation of both the unblocked P2Y1 and the P2Y12 receptor and is correlated with protein expression of P2Y12
    Oscar Ö Braun
    Stefan Amisten
    Anna-Karin Wihlborg
    Karen Hunting
    David Nilsson
    David Erlinge
    Purinergic Signalling, 2007, 3 : 195 - 201
  • [38] The influence of variation in the P2Y12 receptor gene on in vitro platelet inhibition with the direct P2Y12 antagonist cangrelor
    Bouman, Heleen J.
    van Werkum, Jochem W.
    Rudez, Goran
    Leebeek, Frank W. G.
    Kruit, Adrian
    Hackeng, Christian M.
    ten Berg, Jurrien M.
    de Maat, Moniek P. M.
    Ruven, Henk J. T.
    THROMBOSIS AND HAEMOSTASIS, 2010, 103 (02) : 379 - 386
  • [39] Incidence of High On-Treatment Platelet Reactivity in Continuous Flow LVAD Patients Treated with P2Y12 Inhibitors
    Sorensen, E. N.
    Dees, L.
    Feller, E. D.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2017, 36 (04): : S445 - S445
  • [40] Ligand recognition by the human platelet P2Y12 receptor
    von Kuegelgen, Ivar
    Algaier, Irina
    Hoffmann, Kristina
    PURINERGIC SIGNALLING, 2010, 6 (01) : 61 - 61